It is proposed that 200 hospital representatives who intend to optimize the product line may lose their jobs

today, it was announced that the company will make product line adjustments in the near future, mainly related to the following four points:

200 hospital representatives, OTC representatives increased by 400 places, KA increased by 100 places, DM can be transferred to KA;and WGL merge with XLB;Hepatology Independent Team;will have 95 per cent MR this weekend and DM next week; and the second week of December will be almost all set up to begin the handover process gradually.It is not clear whether hospital representatives will have the opportunity to transfer to OTC representatives, according to the layoff of 200, an additional 500 jobs calculated, the company's product line adjustment, will be 300 more jobs.It is reported that the company was formally established on the 16th of this month, by Mylan and Pfizer's business unit Pfizer strong merger. Pfizer is Pfizer's global business group focused on patent expired branded drugs and generics.It is not difficult to see from this architectural adjustment, the company will focus on the layout of the OTC field market, and this move may be a follow-up to the continuous reduction of drug prices.At present, from the domestic policy direction, drug price reduction is the general trend. Band procurement will also further radiate throughout the country, forming a price linkage. In the future, the market share of generic drugs evaluated by consistency will be rapidly increased, and the replacement of imported raw drugs will be accelerated, and multinational pharmaceutical companies will be hit as a result.Drug price reduction normalization, will certainly let enterprises start to adjust the business layout, so there will still be a large number of employees face "job optimization." (Sina Pharmaceutical News
)